Roche Aktie

355,83 EUR +5,54 EUR +1,58 %

06.01.2026

BMN

330,81 CHF +6,79 CHF +2,10 %

06.01.2026

BRX

Roche jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.278,68 Mrd. EUR

KGV24,60Div. Rendite3,80%

WKN855167

ISINCH0012032048

SymbolRHHVF

Roche Aktien News

Sortieren:Datum Meistgelesen

31.01.25Roche Holding AGRoche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

31.01.25GlobeNewswireRoche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

30.01.25Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth

30.01.25GlobeNewswire[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2024 mit Verkaufswachstum von 7%; drittes Quartal in Folge mit 9% Wachstum

30.01.25GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth

29.01.25Roche Holding AGChange to the Roche Enlarged Corporate Executive Committee

29.01.25GlobeNewswireChange to the Roche Enlarged Corporate Executive Committee

28.01.25GlobeNewswireRoche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer

28.01.25Roche Holding AGRoche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer

27.01.25Roche Holding AGRoche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)

27.01.25GlobeNewswireRoche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)

22.01.25GlobeNewswireRoche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care

22.01.25Roche Holding AGRoche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care

13.01.25PR NewswireRoche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma

09.01.25PR NewswireRoche's momentum in digital pathology continues with FDA clearance on its high-volume slide scanner

08.01.25Roche Holding AGRoche purchases shares in tender offer for Poseida Therapeutics, Inc.

08.01.25GlobeNewswireRoche purchases shares in tender offer for Poseida Therapeutics, Inc.

19.12.24GlobeNewswireRoche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease

18.12.24GlobeNewswireRoche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution

13.12.24GlobeNewswireRoche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness

13.12.24GlobeNewswireRoche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities

10.12.24GlobeNewswireNew and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma

09.12.24GlobeNewswireRoche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

08.12.24GlobeNewswireFive-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

05.12.24GlobeNewswireFDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

26.11.24GlobeNewswireRoche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies

26.11.24GlobeNewswireRoche reports update on Phase III SKYSCRAPER-01 study results

25.11.24PR NewswireRoche receives FDA approval for first companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with ZIIHERA

12.11.24PR NewswireFlare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology

05.11.24GlobeNewswireRoche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024

31.10.24GlobeNewswireRoche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease

31.10.24GlobeNewswireNew England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer

23.10.24GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months

23.10.24GlobeNewswire[Ad hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von 9% (CER) auch im dritten Quartal 2024; Konzernverkäufe steigen in den ersten neun Monaten um 6%

18.10.24GlobeNewswireRoche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study

18.10.24PR NewswireRoche receives FDA approval for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY

14.10.24GlobeNewswireMajority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate

11.10.24GlobeNewswireFDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

10.10.24GlobeNewswireRoche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY

08.10.24PR NewswireSurvey commissioned by Roche shows that HPV infection, which causes 99% of all cervical cancer cases, remains largely misunderstood by the general public

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.